01 — At a Glance
The Ayurvedic Unicorn Nobody Talks About
- 52-Week High / Low₹655 / ₹439
- Q3 FY26 Revenue₹1,152 Cr
- Q3 FY26 PAT₹319 Cr
- Q3 EPS (₹)₹7.32
- Annualised EPS (Q3×4)₹29.28
- Book Value₹67.1
- Price to Book6.62x
- Dividend Yield2.25%
- Debt / Equity0.02x
- 9M FY26 Total Dividend₹10/share
Auditor’s Opening Note: Emami closed Q3 FY26 with ₹1,152 crore revenue (+9.75% QoQ, +10% YoY), ₹319 crore PAT, and a 33.4% EBITDA margin — post-GST normalization. The stock rewarded this with a -15.4% return over 3 months. Then they announced a 600% interim dividend (₹6/share) and watched everyone yawn. This is a company printing ₹29/share annual profit, sitting at 24x P/E, trading like a slow-motion FMCG show. Welcome to Emami: the brand everyone uses, the stock nobody cares about.
02 — Introduction
The Fairness Cream Empire That Reinvented Itself Every Five Years
Emami Ltd is what happens when you take Ayurvedic herbs, add celebrity endorsements, and hit distribution like a desi Amazon delivery network. Since 1974 (when it was just “Kemco Chemicals making cosmetics”), the Kolkata-based conglomerate has built a 550-product empire across five manufacturing facilities, 70+ countries, and 5.4 million retail outlets in India alone.
The portfolio reads like your grandmother’s medicine cabinet: BoroPlus (67.7% market share in antiseptic cream — yes, really), Navratna cooling oil (62.8% share), Zandu Ayurvedic range, Kesh King (hair oils that were in free fall before BCG showed up), Dermicool, and the controversial “Smart and Handsome” fairness cream line (rebranded from “Fair and Handsome” in 2025 after the world decided fairness creams were no longer acceptable). They own Helios Lifestyle (The Man Company grooming brand), bought Brillare (salon products), and are parking money in juice companies because apparently herbs alone aren’t enough anymore.
Return on Equity: 30.2%. ROCE: 32.4%. Interest coverage: 83.3x. These ratios don’t lie — but the stock price certainly seems confused about them. Q3 FY26 saw the company pivot hard to rural markets with sachet-focused launches, post-GST pricing normalization is kicking in, and Kesh King is finally climbing out of the grave after being officially dead for two years.
Concall Headline (Feb 2026): Management stated “the fire has to come from rural areas” and committed to selling 10%+ grammage increases in low-unit packs (LUPs) instead of dropping prices. Translation: Emami is going for volume disguised as affordability. The Kesh King relaunch — “relaunched around August, September… with BCG refresh” — is the comeback narrative nobody expected.
03 — Business Model: Herbs, Fairness, and Corporate Drama
550 Products. 5 Factories. One Obsession with Market Share.
Emami’s model is aggressively simple: source Ayurvedic actives, coconut/menthol oils, and chemical inputs; blend them in five domestic manufacturing plants; ship through 3,400 distributors reaching 5.4 million retail outlets; and rake in 26% operating margins without breaking a sweat. International subsidiary network (Bangladesh, Lanka, Russia, Egypt, MENA, Europe) handles the 17% of revenues that come from overseas. E-commerce, quick commerce, modern trade, and general trade all coexist in an omnichannel Frankenstein that somehow works.
Key brands drive revenue: BoroPlus is the franchise (₹1,000+ crore estimated), Navratna (cooling oil empire), Zandu (Ayurvedic healthcare), and Kesh King (medicinal hair oil that was in ICU before the relaunch). Newer bets include The Man Company (premium male grooming), Brillare (salon-quality products), and AloFrut (acquired in Oct 2023 for ₹109.56 crore). Advertising spend runs at 17.7% of sales — aggressive for FMCG, but necessary when your competitors include Unilever, P&G, and Colgate.
The competitive moat? Brand recall in Tier 2/3 towns is insanely strong. Your mom’s dermatologist recommends BoroPlus. The local ayurvedic store stocks Zandu. The barbershop guy uses Kesh King (after the relaunch, at least). That’s not a moat — that’s a fortress.
BoroPlus67.7%Market Share
Navratna62.8%Market Share
Domestic Rev83%Of Portfolio
Intl Markets70+Countries
GST 2.0 Chaos: In February 2025, GST rate cuts hit cosmetics and herbal products hard. Emami’s response? Don’t cut prices on small packs (₹50–100) because e-commerce and modern trade viability collapses. Instead, increase grammage by 10–12% and call it “affordability.” Works for rural. Confuses urban consumers. But whatever works, right?
💬 Are you a BoroPlus loyalist or do you think Emami’s empire is overrated? Drop your hot take in the comments!
04 — Financials Overview
Q3 FY26: The Numbers Post-GST Mayhem
Result type: Quarterly Results | Q3 FY26 EPS: ₹7.32 | Annualised EPS (Q3×4): ₹29.28 | Full-year TTM EPS: ₹18.20
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,152 | 1,049 | 799 | +9.8% | +44.2% |
| Operating Profit (EBITDA) | 384 | 334 | 177 | +14.9% | +116.9% |
| EBITDA Margin % | 33.4% | 31.8% | 22.2% | +160 bps | +1,120 bps |
| PAT | 319 | 279 | 148 | +14.3% | +115.5% |
| EPS (₹) | 7.32 | 6.39 | 3.40 | +14.6% | +115.3% |
P/E Reality Check: Full-year TTM EPS ₹18.20 ÷ CMP ₹445 = P/E 24.4x (screener shows 24.2x — rounding variance). Sector median P/E is 45.9x (yes, FMCG is insanely expensive). Emami at 24x is trading at a 47% DISCOUNT to the industry median. Yet the stock fell -15.4% in three months while printing ₹7.32 per quarter. This is not a valuation problem. This is an “investor indifference” problem.
05 — Valuation: Fair Value Range
What’s This Ayurvedic Empire Really Worth?
Join 10,000+ investors who read this every week.
